A recent jury verdict ordering Abbott Laboratories to pay $70 million in damages is the latest development in ongoing litigation over preterm infant formulas and their alleged connection to necrotizing enterocolitis (NEC), a serious condition affecting premature babies.
The Illinois trial involved claims that Abbott failed to adequately warn about the risks associated with its cow’s milk-based formula products used in neonatal intensive care units (NICUs). The jury awarded both compensatory and punitive damages, reflecting not only the injuries involved but also its findings related to the company’s conduct.
The decision adds to a growing number of state-court verdicts that are shaping the trajectory of NEC baby formula litigation nationwide.
Inside the NEC Claims Against Formula Manufacturers
The NEC baby formula lawsuits center on whether manufacturers of preterm infant formula failed to provide sufficient warnings about the potential link between cow’s milk-based formula and NEC in premature infants.
NEC is a severe gastrointestinal disease that can cause inflammation, tissue death, and intestinal perforation. It occurs most often in preterm babies, whose digestive and immune systems are still developing. In serious cases, the condition can lead to sepsis, multiple surgeries, long-term complications, or death.
Families bringing these claims point to decades of medical research suggesting that formula-fed premature infants may face a higher risk of NEC compared to those fed breast milk or donor milk. They argue that this information should have been more clearly communicated to hospitals and parents making critical feeding decisions in the NICU.
Manufacturers have consistently denied these allegations, maintaining that their products are safe and provide necessary nutrition in neonatal intensive care settings. They argue that factors related to early birth and underdeveloped systems, rather than formula, are the primary risk factors for NEC.
Medical organizations, including the American Academy of Pediatrics, have said that human breast milk may reduce the risk of NEC but doesn’t eliminate it in premature infants, and that specialized formula is often needed in NICUs when alternatives are limited.
Why State Court Trials Are Playing a Key Role in NEC Litigation
While hundreds of NEC lawsuits have been consolidated into multidistrict litigation (MDL) in federal court, many of the most significant developments so far have taken place in state courtrooms.
The federal MDL, centralized in the Northern District of Illinois, is designed to handle shared pretrial issues such as discovery and expert testimony. Bellwether trials in that proceeding are expected to test key arguments, but to date, no NEC case in the MDL has yet resulted in a settlement or jury verdict.
Individual state court cases have already gone to trial, allowing juries to weigh competing scientific and medical evidence. These verdicts are drawing attention because they may offer early signs about how similar claims could be resolved more broadly.
What Recent NEC Verdicts Reveal About These Cases
The $70 million award follows several other high-profile NEC trial outcomes, including a $495 millon verdict against Abbott and a $60 million verdict against Mead Johnson. Some defense victories and post-trial rulings have shown that results are far from uniform.
That variation reflects the complexity of the litigation. NEC cases often hinge on difficult questions about causation, including whether formula use increases risk or whether the condition is primarily driven by early birth and other medical factors.
Jurors are also being asked to evaluate failure-to-warn claims, specifically, whether manufacturers had a duty to provide stronger or more explicit warnings based on the available scientific literature. These are not straightforward determinations, and outcomes can vary significantly depending on how evidence is presented and interpreted in each case.
Even so, early verdicts are beginning to offer insight into how these claims may be viewed. State court outcomes, such as the recent Illinois case, can influence how both plaintiffs and defendants approach future trials, including decisions about expert testimony, case selection, and potential settlement strategies.
They may also shape how juries in other jurisdictions evaluate similar claims as more cases move toward trial. Meanwhile, the federal MDL continues to develop, with additional cases being prepared and key legal and scientific questions still unresolved.
Outside of the courtroom, these cases are also raising questions for families. Many parents say they were focused on their baby’s care in the NICU and only later began to wonder about feeding decisions, available alternatives like donor breast milk, and what they were told at the time.
As more NEC cases move forward, those questions about what was known and what should have been shared are likely to remain a central issue in the litigation.
